Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:ATC_code
|
| gptkbp:ATCCode |
gptkb:N04B
|
| gptkbp:class |
gptkb:Anatomical_Therapeutic_Chemical_Classification_System
|
| gptkbp:excludes |
anticholinergic agents
|
| gptkbp:includes |
gptkb:Levodopa
MAO-B inhibitors Dopamine agonists COMT inhibitors |
| gptkbp:partOf |
gptkb:N04_(Anti-Parkinson_drugs)
|
| gptkbp:regulates |
dopaminergic neurotransmission
|
| gptkbp:routeOfAdministration |
oral
parenteral |
| gptkbp:treatment |
motor symptoms of Parkinson's disease
|
| gptkbp:usedFor |
gptkb:Parkinson's_disease
|
| gptkbp:bfsParent |
gptkb:N04BB
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
N04B (Dopaminergic agents)
|